The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of tertiary lymphoid structures with outcomes from PD-1 inhibition in advanced malignant pleural mesothelioma.
 
Krisztian Homicsko
Research Funding - BMS Global; MSD; Owkin (Inst); ROCHE
 
Giota Zygoura
No Relationships to Disclose
 
Stephanie Tissot
No Relationships to Disclose
 
Sanjay Popat
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; EQRx; GlaxoSmithKline; Guardant Health; Incyte; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Roche; Sanofi; Seagen; Takeda; Turning Point Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; EQRx; GlaxoSmithKline; Guardant Health; Incyte; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Pfizer; Roche; Sanofi; Seagen; Takeda; Turning Point Therapeutics
Research Funding - Amgen (Inst); ARIAD (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics; MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trizell; Turning Point Therapeutics (Inst)
Expert Testimony - Merck KGaA; Roche
 
Alessandra Curioni-Fontecedro
No Relationships to Disclose
 
Tereza Dellaporta
No Relationships to Disclose
 
Mary O'Brien
No Relationships to Disclose
 
Anthony Pope
No Relationships to Disclose
 
Riyaz N.H. Shah
Honoraria - AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; EQRx; Guardant Health; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; EQRx; Guardant Health; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; EQRx; Guardant Health; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); EQRx (Inst); Guardant Health (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; EQRx; Guardant Health; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
(OPTIONAL) Uncompensated Relationships - ALK; British Thoracic Oncology Group; EGFR Positive UK; Roy Castle Lung Cancer Foundation
 
Rosita Kammler
No Relationships to Disclose
 
Stephen P. Finn
Honoraria - AstraZeneca; MSD; Roche; SERVIER
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Pfizer
 
George Coukos
No Relationships to Disclose
 
Solange Peters
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ecancer (Inst); Ecancer (Inst); Fishawack Facilitate (Inst); Illumina (Inst); Imedex (Inst); Incyte (Inst); medscape (Inst); Medtoday (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); OncologyEducation (Inst); Peerview (Inst); PER (Inst); Pfizer (Inst); Prime Oncology (Inst); Research to Practice (Inst); RMEI Medical Education (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Biocartis (Inst); Bioinvent (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-Star Biotechnology (Inst); Foundation Medicine (Inst); Genzyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Illumina (Inst); Incyte (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Phosplatin Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst); Vaccibody (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Annals of Oncology (I); ESMO; ETOP Scientific chair; JTO Past Deputy Editor; SAMO President
 
Rolf A. Stahel
No Relationships to Disclose